Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization [Yahoo! Finance]
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 [Yahoo! Finance]
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
Ascendis Pharma A/S (ASND) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.